Showing 1111-1120 of 23044 results for "".
Relapse Management in Multiple Sclerosis: Corticosteroids Remain the Linchpin of Therapies
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/relapse-management-in-multiple-sclerosis-corticosteroids-remain-the-linchpin-of-therapies/32084/Several modalities are available for the treatment of multiple sclerosis relapse, including corticosteroids, intravenous immunoglobulins, and therapeutic apheresis.Conference Coverage Highlights From the 2012 Alliance for Continuing Education in the Health Professions (ACEHP) Annual Conference, Part 2
https://reachmd.com/programs/conference-coverage/conference-coverage-highlights-from-the-2012-alliance-for-continuing-education-in-the-health-professions-acehp-annual-conference-part-2/6570/Join host Lawrence Sherman at this year's meeting of the Alliance for Continuing Education in the Health Professions (ACEHP), formerly the Alliance for CME, held on January 21-24, 2012 in Orlando, Florida. His two guests are: Dr. Sharon Confessore, Director of Change Management and Learning at Bon3 Ways to Provide Care & Compassion in a Pandemic
https://reachmd.com/programs/covid-19-frontlines/3-ways-to-provide-care-compassion-in-a-pandemic/11645/The chaos and uncertainty brought on by COVID-19 may make us forget the simple actions we can do to stay connected with others.Genetic Testing in Adults with Epilepsy
https://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/genetic-testing-in-adults-with-epilepsy/32052/Appropriate treatment of adults with epilepsy requires the practitioner to be familiar with indications for genetic testing, approaches to testing, diagnostic yield, and clinical ramifications of the results.Immunotherapy: Changing Patient Outcomes in SCLC
https://reachmd.com/programs/cme/immunotherapy-changing-patient-outcomes-in-sclc/10710/This activity offers expert insight into the practice-changing evidence on immunotherapy for the management of extensive-stage small cell lung cancer.Pivotal Data in Anti-PD-1 Strategies for HER2-Negative Upper GI Cancers
https://reachmd.com/programs/cme/pivotal-data-in-anti-pd-1-strategies-for-her2-negative-upper-gi-cancers/37690/Partnering with Patients: Improving First-Line Treatment Selection in Upper GI Cancers Through Shared Decision-MakingDistinguishing First-Line Treatment Adverse Event Profiles in HER2-Negative Upper GI Cancers
https://reachmd.com/programs/cme/distinguishing-first-line-treatment-adverse-event-profiles-in-her2-negative-upper-gi-cancers/37691/Partnering with Patients: Improving First-Line Treatment Selection in Upper GI Cancers Through Shared Decision-MakingShared Decision-Making in Pulmonary Arterial Hypertension: Strategies for PAH Treatment Initiation and Support
https://reachmd.com/programs/medical-industry-feature/shared-decision-making-in-pah-treatment-initiation/36303/Early diagnosis and intervention are critical for improving outcomes for patients with pulmonary arterial hypertension (PAH).1,2 Evidence-based guidelines recommend adding UPTRAVI® (selexipag)—a prostacyclin receptor agonist—at first follow-up for appropriate patients presenting at intermediate-lowSafety Monitoring of Disease-Modifying Therapies in Multiple Sclerosis
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/safety-monitoring-of-disease-modifying-therapies-in-multiple-sclerosis/32085/Guidance in disease-modifying therapy selection and appropriate safety monitoring are important roles of the clinician caring for people with multiple sclerosis.Consensus Panel Highlights: Pharmacotherapy for Presbyopia and Considerations for the Posterior Segment
https://eyehealthacademy.org/programs/cme/Consensus-Panel-Highlights-Pharmacotherapy-for-Presbyopia-and-Considerations-for-the-Posterior-Segment/36580/This supplement summarizes a panel discussion among optometrists and retina specialists who convened to discuss the expanding armamentarium of presbyopia-correcting eye drops and establish a set of best practices regarding diagnostic testing, patient candidacy, and follow-up regimens.